Health Plan Weekly

  • Health Care Lobbying Rose 70% in 20 Years

    Lobbying spending by the health care industries reached $713.6 million in 2020, a 70% increase over the past two decades, according to a recent JAMA Health Forum analysis based on data compiled by OpenSecrets. The growth was mainly driven by pharmaceutical and health product manufacturers and providers. Expenditures were highly concentrated among a small subset of firms, especially for payers, with the top 10% of health plans responsible for 70.4% of spending.
  • Cigna-Walgreens Joint Venture Means New Risk-Based Contracting Test

    Cigna Corp. on Nov. 7 took a $2.5 billion position in VillageMD, a primary care provider owned by Walgreens Boots Alliance, Inc., contributing to VillageMD’s move to acquire a fellow provider. The Cigna investment is just the latest of a flurry of cash-funded insurer deals involving providerstech startups and brick-and-mortar retail firms. Health care insiders say the spending spree is far from over, and that the deal is a chance for Cigna’s Evernorth division to field-test its value-based contracting services at its largest scale yet. 
  • UnitedHealth Survey Finds Large Increase in Number of People Using Virtual Care

    A recent survey from UnitedHealthcare found that 71% of respondents said they would likely use virtual care in the future, up from 53% in last year’s survey. Donna O’Shea, M.D., UnitedHealth’s chief medical officer of population health, tells AIS Health that the results indicate the use of virtual care is more than just a COVID-19-specific trend and is likely to become a permanent part of health care. 

    Still, that’s not to say that people prefer virtual care over visiting doctors in their offices. In fact, the 2022 UnitedHealthcare Consumer Sentiment Survey found that 60% of respondents preferred in-person appointments for non-emergency issues such as allergies, flu or rashes, while 26% preferred virtual appointments and 14% had no preference. The question assumed that the quality and costs of care were comparable between in-person and virtual settings.  

  • Severe Flu Season Won't Do Much Harm to Health Insurers’ Earnings Growth

    Influenza cases and hospitalizations — which dipped in 2020 and 2021 as the public took steps like masking and staying home to slow transmission of COVID-19 — are back this year with a vengeance.  

    But while one equities analyst recently warned investors that such “heightened flu activity” could impact financial metrics for payers that haven’t priced for such a scenario, a credit rating analyst tells AIS Health, a division of MMIT, that insurers aren’t likely to take a major hit. 

  • News Briefs: Centene Inks Deal to Spin Off Magellan Specialty Health

    Centene Corp. said on Nov. 17 that it reached a deal with Evolent Health, Inc. to sell the insurer’s subsidiary Magellan Specialty Health. Centene acquired Magellan Specialty Health — which offers utilization management solutions to health plans related to radiology, musculoskeletal care, physical medicine and genetic testing — in January 2022, when it bought the firm’s parent company, Magellan Health, Inc. The deal is part of Centene’s “value creation plan” in which it is spinning off other divisions, including the PBM Magellan Rx. Centene said it expects to receive approximately $600 million in proceeds at closing, and has the opportunity to receive another $150 million in cash and Evolent common stock in 2024 “if certain performance metrics are achieved.” The transaction is subject to U.S. federal antitrust clearance and other customary closing conditions, and it’s expected to close in the first half of 2023. 
The Latest
Meet Our Reporters

Meet Our Reporters

×
×
×